Abstract:Abstract OBJECTIVES End-stage congenital heart disease (CHD) in children with heterotaxy syndrome might necessitate a heart transplant (HTx). An HTx in heterotaxy patients can be associated with several technical (e.g. redo, systemic/pulmonary-venous/situs anomalies, pulmonary artery reconstruction) and extra-cardiac (e.g. ciliary dyskinesia, infections, gastrointestinal) challenges. Our goal was to determine if heterotaxy syndrome is associated with increased early or late transplant risks. METHODS The United Network for Organ Sharing transplant database was merged with the Paediatric Health Information System administrative database to identify children with heterotaxy who received an HTx. Characteristics and outcomes were compared between children with heterotaxy and contemporaneous non-heterotaxy congenital and non-congenital cardiomyopathy control groups. RESULTS After we merged the databases, we divided our cohort of 1122 patients into 3 groups: the heterotaxy (n = 143), group the non-heterotaxy congenital (n = 428) group and the cardiomyopathy (n = 551) group. There were differences in the characteristics between the 3 groups, with the heterotaxy group being comparable to the non-heterotaxy congenital group. The waiting list duration was longer for the heterotaxy than for the non-heterotaxy congenital and cardiomyopathy groups (91 vs 63 vs 56 days, P < 0.001). Early post-transplant complications were similar for all groups except for operative mortality, which was 1% for the cardiomyopathy and 4% for the heterotaxy and non-heterotaxy congenital groups (P < 0.001). The post-transplant hospital stay was shorter for the cardiomyopathy (57 days) compared to the non-heterotaxy congenital (99 days) and heterotaxy (89 days) groups (P < 0.001). Whereas rejection prior to discharge was comparable between the heterotaxy and the CHD groups, it was higher at 1 year for the heterotaxy (22%) than for the non-heterotaxy congenital (19%) and cardiomyopathy (13%) groups (P < 0.001). Survival at 5 years was superior for the cardiomyopathy (87%) compared to the heterotaxy (69%) and non-heterotaxy congenital groups (78%) (P < 0.001). For the heterotaxy group, no risk factors affecting survival were identified on multivariable analysis. CONCLUSIONS Regardless of the complexity, an HTx in selected children with heterotaxy is associated with good mid-term outcomes. Despite early results that are comparable to those of other patients with CHD, the increasing rejection rate at 1 year and the relatively accelerated attrition at mid-term warrant further follow-up. Due to database limitations in defining morphologic and surgical details, further work is warranted to delineate anatomical and surgical variables that could affect survival.

Sequential – second and third – transplants in patients with heterotopic heart allografts

Orthotopic transplantation after implantation of a Jarvik 7 total artificial heart

[Orthotopic Heart Transplantation: Clinical Experience on 56 Patients].

[Second Transplantation for 22 Patients with Graft Failure after First Allogeneic Stem Cell Transplantation].

Retransplantation ? the Only Means to Save Recipient's Life after Failure of Liver Transplantation: a Report of 774 Cases

Recurrent giant cell myocarditis following orthotopic heart transplant resulting in urgent redo orthotopic heart transplantation: a case report

Heart transplantation in Finland 1985-1995

Four Decades of Progress in Heart-Lung Transplantation: 271 Cases at a Single Institution.

Short-term outcomes after third-time lung transplantation: A single institution experience

Heart Transplantation after Univentricular Palliation: Improved Outcomes and Increased Complexity

In vivo mitral valve repair for the transplanted donor heart in orthotopic heart transplantation

Second and Third Kidney Transplants.

Preliminary Experience of 11 Successful Orthotopic Heart Transplantations

Survival, function, and immune profiling after beating heart transplantation

Outcomes of heart transplants in children with heterotaxy syndrome

The HeartMate 3 left ventricular assist device as a strategy to bridge to transplant

Orthotopic Heart Transplantations for End-Stage Heart Diseases

Experience of 3 Cases of Orthotopic Heart Transplantation in Perioperative Period

Operative Experience of Orthotopic Heart Transplantation

Outcome after heart transplantation from donation after circulatory-determined death donors

Postoperative Management of Orthotopic Homologous Heart Transplantation in Ten Cases